SEC Form 4 · accession 0001349297-26-000010
Roivant Sciences Ltd. · ROIV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Meghan Fitzgerald
Director
Period of report
Sep 16, 2026
Accepted (ET)
Sep 18, 2026 · 6:57 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001635088
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common SharesF1 | Sep 16, 2026 | A | 5,054 | $0.00 | A | 41,162 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $39.57 | Sep 16, 2026 | A | 10,531 | A | — | Sep 15, 2036 | Common Shares | 10,531 | 10,531 | D |
Explanation of responses
- F1Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date.
- F2Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date.